Emmes Group, a leading global technology-focused contract research organization (CRO), announced a multi-year strategic partnership with Miimansa AI. A critical pillar of the partnership, which aims to revolutionize clinical research at Emmes, is the acquisition of Miimansa’s Clinical Entity Modeling tools based on modern Large Language Modeling (LLM) techniques and generative AI.
Artificial intelligence (AI) will fundamentally change all aspects of healthcare – including clinical research. The Emmes Group is rapidly developing its Veridix AI technology platform. Miimansa’s Clinical Entity Modeling technology will be an important building block to accelerate the development of state-of-the-art automated text processing solutions for clinical research.
The focus of the partnership is on creating capabilities to quickly and accurately process large amounts of clinical data and convert text to text, for example for protocol and medical document creation, thereby reducing the time and cost of manual data processing and analysis.
Also Read: MasterControl Makes GxPAssist AI Generally Available to Streamline Life Science Processes
“We are excited to collaborate with Miimansa AI to bring cutting-edge AI technology to clinical research,” said Sastry Chilukuri , CEO at Emmes Group. “The clinical entity modeling tools acquired through our partnership will accelerate the development and deployment of Emmes Group’s Concord GenAI platform to enable faster, better and more efficient clinical trials.”
Dr. Vibhu Agarwal , Founder and CEO of Miimansa AI, adds: “Collaborating with Emmes Group is an important milestone for us. Their expertise and extensive clinical trial data represent a unique opportunity to apply our advanced AI techniques in practice. Together, we aim to transform clinical research to make it faster, more affordable and ultimately more successful in delivering safe and effective therapies.”
Source: PRNewswire
